This inventor holds 24 USPTO granted patents and 8 published patent applications, plus 2 CIPO patents and 7 EPO patents, primarily in Pharmaceutical Compounds. Top assignees: Heptares Therapeutics Limited, Nxera Pharma UK Limited, Centessa Pharmaceuticals (UK) Limited. Active years: 2016-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Hertfordshire, GB (2016)
- Welwyn Garden City, GB (2017 - 2019)
- Welwyn Garden, GB (2017 - 2019)
- Cambridge, GB (2019 - 2023)
Company Filing History:
18 out of 85 
5 out of 18 
1 out of 12 Years Active: 2016-2026
Areas of Expertise:
Title: An Insight into the Innovations of John Andrew Christopher
Introduction: John Andrew Christopher is a prominent figure in the field of pharmaceuticals and biotechnology, based in Cambridge, GB. With an impressive portfolio of 20 patents, his work primarily focuses on advancing treatments for neurological and psychiatric disorders. His innovative approach to drug development has played a significant role in shaping the landscape of therapeutic options available today.
Latest Patents: Among his recent contributions, two noteworthy patents stand out. The first is related to "Orexin 1 receptor antagonists," involving novel compounds aimed at treating, preventing, ameliorating, controlling, or reducing the risk of neurological or psychiatric disorders associated with orexin receptors. The second patent centers around "CGRP receptor antagonists," which also details novel compounds designed for similar therapeutic purposes. These advancements demonstrate Christopher's commitment to addressing critical health challenges.
Career Highlights: Throughout his career, John Andrew Christopher has made significant strides in pharmaceutical innovation. He has been associated with notable companies such as Heptares Therapeutics Limited and Nxera Pharma UK Limited. His work at these organizations has allowed him to contribute to pioneering research and development initiatives, enhancing the overall efficacy of treatments available for patients.
Collaborations: Collaboration has been key to Christopher's success. He has worked closely with esteemed colleagues like Miles Stuart Congreve and Benjamin Gerald Tehan, sharing insights and expertise to propel their mutual goals forward. This teamwork underscores the importance of collaboration in innovation, enabling the development of groundbreaking therapeutic solutions.
Conclusion: John Andrew Christopher's contributions to the fields of pharmaceuticals and biotechnology have been immensely impactful. With a focus on developing new treatments for neurological and psychiatric disorders, his innovative patents and collaborative efforts position him as a pivotal figure in the ongoing evolution of medical science. His work exemplifies the power of ingenuity and collaboration in addressing complex health challenges.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile